A microRNA signature profile in EBV+ diffuse large B-cell lymphoma of the elderly.

Journal Article (Journal Article;Multicenter Study)

Currently, there is no characteristic microRNA (miRNA) expression pattern in Epstein-Barr virus+ diffuse large B-cell lymphoma of the elderly (EBV+DLBCLe). This study aims to characterize a signature profile and identify miRNAs that can be used as biomarkers and alternative therapeutic targets for EBV+DLBCLe. Seventy-one DLBCL patients aged 50 years and older were included and four EBV+ and four EBV- samples were analyzed in two miRNA array platforms (pilot study). A larger multicenter cohort (29 EBV+DLBCLe and 65 EBV-DLBCL patients) was used to validate the results by real-time polymerase chain reaction. In the pilot study, 9% of DLBCL were EBV+DLBCLe by in situ hybridization. In multicenter study, EBV+DLBCLe group showed a predominance of non-germinal center B-cell origin. Overall survival duration of EBV+DLBCLe was significantly inferior to that of EBV-DLBCL patients. We found 10 deregulated miRNAs in the two groups, but only seven were statistically different. We confirmed overexpression of hsa-miR-126, hsa-miR-146a, hsa-miR-146b, hsa-miR-150, and hsa-miR-222 and underexpression of hsa-miR-151 in EBV+DLBCLe cases compared to EBV-DLBCL cases. Hsa-miR-146b and hsa-miR-222 showed high specificity for identifying EBV+DLBCLe. The present study proposed a miRNA signature for EBV+DLBCLe and our findings suggest that hsa-miR-146b and hsa-miR-222 could be biomarkers and therapeutic targets.

Full Text

Duke Authors

Cited Authors

  • Andrade, TAD; Evangelista, AF; Campos, AHF; Poles, WA; Borges, NM; Camillo, CMC; Soares, FA; Vassallo, J; Paes, RP; Zerbini, MC; Scapulatempo, C; Alves, AC; Young, KH; Colleoni, GWB

Published Date

  • December 15, 2014

Published In

Volume / Issue

  • 5 / 23

Start / End Page

  • 11813 - 11826

PubMed ID

  • 25544772

Pubmed Central ID

  • PMC4322989

Electronic International Standard Serial Number (EISSN)

  • 1949-2553

Digital Object Identifier (DOI)

  • 10.18632/oncotarget.2952


  • eng

Conference Location

  • United States